Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CE-224535

Catalog No: tcsc0006791

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Specifications

CAS No:
724424-43-5

Formula:
$C_{22}H_{29}ClN_4O_6$

Pathway:
Membrane Transporter/Ion Channel

Target:
P2X Receptor

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
PF-04905428

Observed Molecular Weight:
480.94

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CE-224535 is a selective **$P2X_7$ receptor** antagonist.

IC50 & Target: $P2X_7$ receptor[1]

In Vitro: CE-224535 is developed as a disease-modifying antirheumatic drugs (DMARD) and is a selective antagonist of the human $P2X_7$ receptor. CE-224535 can reduce leukocyte secretion of IL-1 and IL-18, thereby providing a novel therapeutic approach for treatment of rheumatoid arthritis (RA)[1].

In Vivo: In rats, CE-224535 has low CL_p (11 mL/min/kg) and a large V_{dss} of 7.6 L/kg, which results in a half-life of 2.4 h. Upon oral administration to rats at 5 mg/kg, CE-224535 provides maximal plasma exposure (C_{max}) that is ~90 fold over its IC_{90} in human blood (C_{max}=0.21 μg/mL or 0.44 μM). The oral bioavailability of CE-224535 is low in rats (F=2.6%), but this is believed to be a rat specific phenomenon since corresponding oral bioavailability in both dog (59%) and monkey (22%) is adequate[2].